Hendrik Seeliger

11PUBLICATIONS
32CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Dec 08, 2025
Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.

Ioannis Pozios, Nina N Seel, Nina A Hering

|Oct 31, 2023
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.

Beate Rau, Hauke Lang, Alfred Koenigsrainer

|Jan 21, 2023
Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer.

Nina A Hering, Emily Günzler, Marco Arndt

|Dec 10, 2022
Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.

Ioannis Pozios, Nina A Hering, Emily Guenzler

|Feb 15, 2022
Is Laterality Prognostic in Resected KRAS-Mutated Colorectal Liver Metastases? A Systematic Review and Meta-Analysis.

Michail Belias, Kazunari Sasaki, Jane Wang

|Jan 27, 2022
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.

Lucas D Lee, Ioannis Pozios, Verena Liu

Pageof 2

Frequent Collaborators

2 joint publications

Nina A Hering

2 joint publications

Ioannis Pozios

2 joint publications

Katharina Beyer

2 joint publications

Carsten Kamphues